Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
You can also add 2.0mL for a 5mg/mL concentration that provides better accuracy for lower doses
Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide in Human Volunteers
Withanolides are naturally occurring steroidal lactones derived from an ergostane framework, and their structural diversity, arising from variations in oxidation, hydroxylation, and glycosylation, underlies their multitarget biological effects
\n\n\n\n BPC stands for Body Protection Compound
Sie erfordern vertiefte Kenntnisse der Prozesse und Ablufe sowie der Regelwerke und gesetzlichen Vorgaben, die eingehalten werden mssen